Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Spero Therapeutics (Nasdaq: SPRO) announced that on November 3, 2025 its Compensation Committee approved an inducement grant of 90,000 restricted stock units (RSUs) to one newly hired employee under the 2019 Inducement Equity Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs vest in four equal annual installments beginning December 1, 2025, subject to the employee’s continued employment, and are governed by the 2019 Inducement Plan and an RSU agreement.

CAMBRIDGE, Mass., Nov. 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on November 3, 2025, the Compensation Committee of Spero’s Board of Directors approved the grant of an aggregate of 90,000 restricted stock unit awards (RSUs) to one new employee under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended (2019 Inducement Plan). The RSUs are being granted as an inducement material to Spero’s new employee in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Spero (or following a bona fide period of non-employment), as a material inducement for such individuals entering into employment with Spero, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

The RSUs will vest in four equal annual installments beginning on December 1, 2025, subject to the employees‘ continued employment with Spero on such vesting dates. The RSUs are subject to the terms and conditions of the 2019 Inducement Plan and an RSU agreement covering the grant.

About Spero Therapeutics
Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and MDR bacterial infections with high unmet need. For more information, visit www.sperotherapeutics.com.

Investor Relations Contact:
Shai Biran, PhD
Spero Therapeutics
IR@Sperotherapeutics.com

Media Inquiries:
media@sperotherapeutics.com

FAQ

What did Spero Therapeutics (SPRO) announce on November 28, 2025 about equity grants?

Spero announced a grant of 90,000 RSUs to one new employee approved November 3, 2025 under its 2019 Inducement Plan.

What is the vesting schedule for the 90,000 RSUs granted by SPRO?

The RSUs vest in four equal annual installments beginning December 1, 2025, subject to continued employment.

Why did Spero use the 2019 Inducement Plan for the SPRO RSU grant?

The 2019 Inducement Plan is used to grant equity as a material inducement to individuals not previously employed by Spero, per Nasdaq Rule 5635(c)(4).

Does the SPRO inducement grant require shareholder approval?

The grant was approved by the Compensation Committee under the 2019 Inducement Plan and is compliant with Nasdaq Listing Rule 5635(c)(4) as an inducement award.

How many employees received RSUs in Spero's November 2025 inducement announcement?

A single new employee received an aggregate of 90,000 RSUs.

Where can investors find the terms governing the SPRO RSU award?

The RSUs are subject to the 2019 Inducement Plan and a separate RSU agreement that sets the award terms and conditions.